Diligence and Annual Reports. (Section 6.7) • Alnylam is required to use Commercially Reasonable Efforts to Develop and Commercialize an Alnylam Royalty Product. • Alnylam is required to deliver to Tekmira an annual report, due no later than December 31 of each Contract Year during the Agreement Term, which summarizes the major activities undertaken by Alnylam during the preceding 12 months to Develop and Commercialize its Royalty Products in the applicable field. The report will include an outline of the status of any such Royalty Products in clinical trials and the existence of any sublicenses with respect to such Royalty Products which have not been previously disclosed. Financial Obligations (Sections 7.2-7.4 and 6.1.3)
Appears in 3 contracts
Samples: License and Collaboration Agreement (Regulus Therapeutics Inc.), License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.), License Agreement (Isis Pharmaceuticals Inc)
Diligence and Annual Reports. (Section 6.7) • · Alnylam is required to use Commercially Reasonable Efforts to Develop and Commercialize an Alnylam Royalty Product. • · Alnylam is required to deliver to Tekmira an annual report, due no later than December 31 of each Contract Year during the Agreement Term, which summarizes the major activities undertaken by Alnylam during the preceding 12 months to Develop and Commercialize its Royalty Products in the applicable field. The report will include an outline of the status of any such Royalty Products in clinical trials and the existence of any sublicenses with respect to such Royalty Products which have not been previously disclosed. Financial Obligations (Sections 7.2-7.4 and 6.1.3)
Appears in 1 contract
Samples: License and Collaboration Agreement (Isis Pharmaceuticals Inc)